Artiklar om osteoporos

Reviewartiklar

  1. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019 Jan 26;393(10169):364-376.
  2. Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. Endocr Rev. 2019 Apr 1;40(2):333-368.
  3. Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med. 2019 Apr;285(4):381-394. doi: 10.1111/joim.12873. Epub 2019 Jan 18. PMID: 30657216.
  4. Buckley L, Humphrey MB. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018 Dec 27;379(26):2547-2556.
  5. Black DM,Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. The New England journal of medicine. 2016;374:254-62.
  6. Lorentzon M,Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277:650-61
  7. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405. PMID: 25414052.
  8. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA; EU Review Panel of IOF. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(1-2):137. doi: 10.1007/s11657-013-0137-0.
  9. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22:2395-411.
  10. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008 Apr 3;358(14):1474-82.
  11. Johnell O, Kanis JA, Jonsson B, et al. The burden of hospitalised fractures in Sweden. Osteoporos Int. 2005;16:222-8
  12. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series. 1994;843:1-129.

Läkartidningen om osteoporos:

  1. Wallander, M et al. Rätt behandling under pandemin vid hög risk för allvarliga frakturer – Läkartidningen 2020, Jul 2.
  2. Kharazmi M, Schilcher J, Hallberg P, Michaëlsson K. Atypisk femurfraktur en allvarlig komplikation till bisfosfonater – Läkartidningen 2019 Sep 16;116:FMUU. Swedish. PMID: 31529420.
  3. Larsson Wexell C, Kjellman A, Akre O. Kunskap om läkemedelsrelaterad käkbensnekros behöver spridas – Läkartidningen 2018 May 25;115:E394. Swedish. PMID: 29809272.
  4. Lovric M, Ribom-Bornefalk E. Fler utreddes för osteoporos efter införande av frakturkedja – Läkartidningen 2016 Nov 1;113:D7HL. Swedish. PMID: 27824387.
  5. Åkesson K, Jutberger H. »Frakturkedjor« är den mest effektiva sekundärpreventionen – Läkartidningen 2016 Nov 1;113:D9HX. Swedish. PMID: 27824389.
  6. Rogmark C, Åkesson K. Fragilitetsfrakturer är fortfarande en utmaning – Läkartidningen 2016 Nov 1;113:D9HZ. Swedish. PMID: 27824390.
  7. Wallander M, Palmér M, Lorentzon M. Bisfosfonater vid osteoporos – Läkartidningen 2016 Apr 12;113:DYWI. Swedish. PMID: 27070393.
  8. Nilsson A, Björnsdottir S. Sekundär osteoporos ett ofta missat tillstånd – Läkartidningen 2016 Nov 1;113:D9H3. Swedish. PMID: 27824391.
  9. Kindmark A, Salminen H. Diagnostik, risk och indikation för behandling av osteoporos – Läkartidningen 2016 Nov 1;113:D9H4. Swedish. PMID: 27824392.
  10. Lorentzon M, Åkesson K, Mellström D, Landin-Wilhelmsen K, Pernow Y, Bergström I, Ljunggren Ö. D-vitamin¬behandling och skeletthälsa – svenska riktlinjer behövs – Rekommendationer från SVOS – Läkartidningen 2014 Sep;111(37):1508-10. Swedish. PMID: 25325102.
  11. Bratt O, Akesson K. Osteoporos vid kastrations-behandling – ett försummat område – Läkartidningen 2011 Sep 28-Oct 4;108(39):1902-5. Swedish. PMID: 22111227.
  12. Johansson H, Kanis JA, Ljunggren O, Ström O, Svensson O, Mellström D. FRAX – modell för att beräkna 10-årsrisken för fraktur – Läkartidningen (lakartidningen.se) 2011 Feb 16-22;108(7):336-9. Swedish. PMID: 21539116.
  13. Sjödén G, Sayed-Noor A, Kadum B, Pettersson U. Bisfosfonat¬behandling kan orsaka stressfraktur – men behandlingsnyttan är betydligt större än risken – Läkartidningen 2010 Oct 13-19;107(41):2482-3. Swedish. PMID: 21137565.
  14. Lorentzon M, Ohlsson C. Osteoporos–en arftlig sjukdom Osteoporos – en ärftlig sjukdom – Läkartidningen (lakartidningen.se) 2006 Oct 4-10;103(40):2970-1. Swedish. PMID: 17115660.

Originalstudier läkemedel

  1. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22. PMID: 28546097.
  2. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England journal of medicine. 2016;375:1532-43.
  3. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Jama. 2016;316:722-33.
  4. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30:934-44.
  5. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-54.
  6. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine. 2009;361:756-65.
  7. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England journal of medicine. 2007;356:1809-22.
  8. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. The New England journal of medicine. 2001;344:333-40.
  9. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England journal of medicine. 2001;344:1434-41.
  10. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. The Journal of clinical endocrinology and metabolism. 2000;85:4118-24.
  11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama. 1998;280:2077-82.
  12. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.

Senast ändrad: 24 maj 2021